Nuvalent Inc - Class A (NUVL) Stock Price

77.52 ▼ -2.02 (-2.54%)
Open: 79.41 Vol: 279.07K Day's range: 76.95 - 79.61 Sep 25, 16:00 EDT
IEX quote, 15 minutes delayed during trading hours. Login or Signup to see real-time data
Free Stock Screener
Loading chart ...
NUVL Technical Analysis
5 mins 30 mins Hourly Daily Weekly
SELL SELL SELL SELL SELL
  5 mins 30 mins Hourly Daily Weekly
MA5 77.49▲ 77.99▼ 78.04▼ 78.74▼ 78.43▼
MA10 77.72▼ 78.05▼ 78.46▼ 79.15▼ 77.75▼
MA20 77.97▼ 78.73▼ 79.72▼ 79.02▼ 77.74▼
MA50 78.02▼ 79.31▼ 79.28▼ 78.28▼ 80.02▼
MA100 78.85▼ 79.30▼ 79.51▼ 77.29▲ 78.41▼
MA200 79.90▼ 79.63▼ 77.74▼ 77.48▲ 52.73▲
  5 mins 30 mins Hourly Daily Weekly
MACD -0.067▼ -0.079▼ -0.305▼ -0.108▼ 0.157▲
RSI 40.720▼ 36.376▼ 39.132▼ 47.568▼ 49.427▼
STOCH 15.777▼ 41.307     14.385▼ 47.760     46.983    
WILL %R -58.647     -78.474▼ -90.300▼ -64.097     -59.299    
CCI -120.481▼ -159.360▼ -94.907     -95.709     -0.865    
Latest Filters Detected On NUVL
RSI $NUVL RSI(14) Crossed Below 50 Set Alert
▼ MACD $NUVL MACD(12,26,9) Crossed Below Signal Line Set Alert
MA $NUVL Price Crossed Below MA(50) Set Alert
MA $NUVL Price Crossed Below MA(26) Set Alert
MA $NUVL Price Crossed Below MA(13) Set Alert
MA $NUVL Price Crossed Below MA(7) Set Alert
Nuvalent Inc - Class A News
Nuvalent to Participate in the UBS 2025 Virtual Oncology Day
Wednesday, September 24, 2025 03:49 AM
Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that James ...
Nuvalent Presents Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC at WCLC 2025
Sunday, September 07, 2025 02:45 AM
Rolling NDA submission for zidesamtinib in TKI pre-treated advanced ROS1-positive NSCLC initiated under FDA's RTOR program, with completion on track for the third quarter of 2025 CAMBRIDGE, Mass., ...
Piper Sandler Initiates Nuvalent (NUVL) Amid Key Cancer Drug Catalysts
Monday, September 01, 2025 06:33 PM
Nuvalent, Inc. (NASDAQ:NUVL) ranks among the best mid-cap stocks with huge upside potential. On August 19, Piper Sandler began coverage of Nuvalent, Inc. (NASDAQ:NUVL) with a price target of $112 and ...
NUVL historical stock data
date open high low close volume
25/09/25 79.41 79.61 76.95 77.52 279,070
24/09/25 81.07 82.81 79.021 79.54 326,491
23/09/25 78.93 81.30 78.50 81.08 324,798
22/09/25 76.28 79.275 75.20 78.90 336,865
19/09/25 80.96 81.97 76.53 76.67 997,353
18/09/25 79.54 81.67 78.72 80.96 234,344
17/09/25 78.83 81.275 78.45 78.64 308,666
16/09/25 79.31 80.67 78.04 78.33 241,588
15/09/25 80.18 80.80 77.88 79.37 403,823
12/09/25 81.99 82.40 80.13 80.47 405,266
Quote Details
52wk Low:55.535
52wk High:106.32
Vol:279.07K
Avg Vol(3m):9.2M
1Y Chng:-24.32%
1M Chng:+0.94%
Add to Watch List
More Information
Index US Composite
Market Cap. 5.59B